


I hereby certify that this correspondence is being electronically filed in the the United States Patent and Trademark Office on April 12, 2010.

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Patent Application
Docket No. TPI.350C1


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Deirdre R. Claytor
Art Unit : 1627
Applicants : Örn Almarsson, Magali Bourghol Hickey, Matthew L. Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
Serial No. : 10/660,202
Filed : September 11, 2003
Conf. No. : 6536
For : Pharmaceutical Co-Crystal Compositions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed.

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of reference cited therein.